Though it causes no permanent damage, NAFLD can progress to nonalcoholic steatohepatitis (NASH), which can result ... either ...

Although all patients with NAFLD need aggressive management of cardiovascular risk factors, it is only patients with NASH who need treatment targeted at the liver disease. None of the currently ...

Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be ...

NASH is a form of non-alcoholic fatty liver disease (NAFLD ... The THR agonist additionally reduced LDL-cholesterol, also linked to worsening NASH, cutting the biomarker by 12% and 16% at the ...

Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...

This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH ... fatty ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by ...